Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 13/20 | 0.38 |
| ▸ | DRD2 | P14416 | 13/20 | 0.38 |
| ▸ | HTR2A | P28223 | 13/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.38 |
| ▸ | HTR2C | P28335 | 5/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.38 |
| ▸ | HRH1 | P35367 | 5/20 | 0.38 |
| ▸ | HTR6 | P50406 | 5/20 | 0.38 |
| ▸ | DRD3 | P35462 | 4/20 | 0.38 |
| ▸ | LSS | P48449 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5360151 | 0.99 | MCHR1 (0.37) | MCHR1HTR1ADRD2HTR2AHRH3 | |
| SCHEMBL5367700 | 0.86 | DRD4 (0.45) | HTR1ADRD2HTR2AHRH3KCNH2 | |
| Hydrochloric Acid SCHEMBL5362477 | 0.85 | BCHE (0.45) | HTR1ADRD2HTR2AHRH3KCNH2 | |
| SCHEMBL5369068 | 0.85 | DRD2 (0.43) | HTR1ADRD2HTR2AHRH3KCNH2 | |
| SCHEMBL5367332 | 0.85 | DRD2 (0.40) | HTR1ADRD2HTR2AHRH3KCNH2 | |
| SCHEMBL5367827 | 0.84 | NPC1 (0.45) | HTR1ADRD2HTR2A | |
| SCHEMBL5361286 | 0.84 | NPC1 (0.45) | HTR1ADRD2HTR2A | |
| SCHEMBL5361292 | 0.84 | NPC1 (0.45) | HTR1ADRD2HTR2A | |
| SCHEMBL5374861 | 0.83 | DRD4 (0.49) | HTR1ADRD2HTR2AADRA1ADRD3 | |
| SCHEMBL5361320 | 0.83 | CYP1A2 (0.42) | HTR1ADRD2HTR2AHRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7253165-B2 | Benzisoxazolyl-, pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists | AVENTIS PHARMACEUTICALS INC. (US) | 2007-08-07 | — | — | US | claimed |
| US-20050107377-A1 | Benzisoxazolyl-,pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists | AVENTIS PHARMACEUTIALS INC. (US) | 2005-05-19 | — | — | US | claimed |
| EP-1216244-B1 | Benzisoxazolyl-, pyridoisoxazolyl- and benzthienyl-phenoxy derivatives useful as D4 antagonists | AVENTIS PHARMA INC (US) | 2003-08-13 | — | — | EP | claimed |
| US-7253165-B2 | Benzisoxazolyl-, pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists | AVENTIS PHARMACEUTICALS INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-7253165-B2 | Benzisoxazolyl-, pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists | AVENTIS PHARMACEUTICALS INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-7253165-B2 | Benzisoxazolyl-, pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists | AVENTIS PHARMACEUTICALS INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-20050107377-A1 | Benzisoxazolyl-,pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists | AVENTIS PHARMACEUTIALS INC. (US) | 2005-05-19 | — | — | US | disclosed |
| EP-1216244-B1 | Benzisoxazolyl-, pyridoisoxazolyl- and benzthienyl-phenoxy derivatives useful as D4 antagonists | AVENTIS PHARMA INC (US) | 2003-08-13 | — | — | EP | disclosed |
| EP-1216244-A1 | Benzisoxazolyl-, pyridoisoxazolyl- and benzthienyl-phenoxy derivatives useful as D4 antagonists | Aventis Pharmaceuticals Inc. (US) | 2002-06-26 | — | — | EP | disclosed |
| WO-2001019821-A1 | BENZISOXAZOLYL-, PYRIDOISOXAZOLYL- AND BENZTHIENYL-PHENOXY DERIVATIVES USEFUL AS D4 ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107377-A1 | Benzisoxazolyl-,pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists | DRD4, DRD2, DRD1 | MCHR1 990/4885HTR1A 25/4885DRD2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.